KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Equity Ratio (2017 - 2025)

Historic Equity Ratio for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to 0.03.

  • Aquestive Therapeutics' Equity Ratio rose 9391.81% to 0.03 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.03, marking a year-over-year increase of 9391.81%. This contributed to the annual value of 0.59 for FY2024, which is 6801.92% up from last year.
  • Latest data reveals that Aquestive Therapeutics reported Equity Ratio of 0.03 as of Q3 2025, which was up 9391.81% from 0.77 recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Equity Ratio high stood at 0.03 for Q3 2025, and its period low was 2.08 during Q3 2022.
  • For the 5-year period, Aquestive Therapeutics' Equity Ratio averaged around 1.14, with its median value being 0.92 (2021).
  • Its Equity Ratio has fluctuated over the past 5 years, first crashed by 15897.91% in 2021, then surged by 9391.81% in 2025.
  • Aquestive Therapeutics' Equity Ratio (Quarter) stood at 1.32 in 2021, then plummeted by 56.79% to 2.08 in 2022, then grew by 10.72% to 1.85 in 2023, then soared by 68.02% to 0.59 in 2024, then skyrocketed by 95.76% to 0.03 in 2025.
  • Its Equity Ratio stands at 0.03 for Q3 2025, versus 0.77 for Q2 2025 and 0.6 for Q1 2025.